Pdl Biopharma Inc (PDLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2010 | 06-2010 | 03-2010 | 12-2009 | 09-2009 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 200,486 | 211,312 | 319,674 | 303,227 | 222,418 |
| Marketable Securities | 26,704 | 12,382 | N/A | N/A | N/A |
| Receivables | 250 | 150 | 150 | 1,050 | 400 |
| Income taxes - deferred | N/A | N/A | N/A | 1,271 | 12,395 |
| Other current assets | 0 | 12,983 | 0 | 0 | 0 |
| TOTAL | $235,308 | $241,113 | $334,116 | $315,836 | $250,417 |
| Non-Current Assets | |||||
| PPE Net | 94 | 109 | 137 | 171 | 205 |
| Investments And Advances | 0 | 9,286 | 0 | 0 | 0 |
| Other Non-Current Assets | 22,105 | 21,023 | 23,998 | 22,404 | 13,829 |
| TOTAL | $22,199 | $30,418 | $24,135 | $22,575 | $14,034 |
| Total Assets | $257,507 | $271,531 | $358,251 | $338,411 | $264,451 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,288 | 177 | 685 | 370 | 221 |
| Accrued Expenses | N/A | 6,406 | 4,521 | 77,852 | 3,381 |
| TOTAL | $209,215 | $307,597 | $417,617 | $293,516 | $266,643 |
| Non-Current Liabilities | |||||
| Long Term Debt | 112,618 | 160,092 | 202,993 | 222,148 | N/A |
| Deferred Revenues | 3,213 | 3,213 | 1,500 | 1,600 | N/A |
| Other Non-Current Liabilities | 240,216 | 238,700 | 238,700 | 238,700 | 238,700 |
| TOTAL | $352,834 | $398,792 | $441,693 | $460,848 | $240,200 |
| Total Liabilities | $562,049 | $706,389 | $859,310 | $754,364 | $506,843 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 139,680 | 119,714 | 119,674 | 119,674 | 119,671 |
| Common Shares | 1,395 | 1,196 | 1,195 | 1,195 | 1,195 |
| Retained earnings | -216,964 | -257,153 | -307,291 | -333,298 | -361,858 |
| Other shareholders' equity | 1,343 | 17,080 | 6,362 | 0 | 0 |
| TOTAL | $-304,542 | $-434,858 | $-501,059 | $-415,953 | $-242,392 |
| Total Liabilities And Equity | $257,507 | $271,531 | $358,251 | $338,411 | $264,451 |